The article reports that Australia has approved the Alzheimer's drug lecanemab after two previous rejections. He describes that according to the amyloid hypothesis, amyloid is believed to be the cause of Alzheimer's disease and on this basis anti-amyloid antibodies such as lecanemab and donanemab are claimed to be "disease modifying". However, it states that many studies focusing on amyloid have not shown significant clinical improvement in patients. Both lecanemab and donanemab reliably remove amyloid plaques in the brain and produce only small statistical improvements in cognitive scales. Specifically, lecanemab slowed the deterioration of the CDR-SB score by 0.45 points over 18 months. Donanemab slowed the decline in CDR-SB by 0.67 points in subjects with low or moderate tau pathology. According to the article, these values are below the threshold of 2 points on the CDR-SB scale, which other authors have estimated as a change representing a significant decrease for the patient.